000			01407cam a22003258i 4500
001			BD-DhNSU-30417
003			BD-DhNSU
005			20240403131936.0
008			240403s2017 enka g b 001 0 eng d
020			_a9781119289746 (pbk.)
040			_aDNLM/DLC _cBD-DhNSU _dBD-DhNSU
041			_aeng
050	0	0	_aRM302.5 _b.W35 2017
082	0	0	_a615/.7042 _223
100	1		_aWaller, Patrick
245	1	3	_aAn introduction to pharmacovigilance / _cPatrick Waller and Mira Harrison-Woolrych.
250			_a2nd ed.
264		1	_aHoboken, NJ : _bJohn Wiley & Sons Inc., _cc2017.
300			_axviii, 170p. : _bill. ; _c22 cm.
504			_aIncludes bibliographical references and index.
505	0		_aWhat is pharmacovigilance and how has it developed? -- Basic concepts -- Types and sources of data -- The process of pharmacovigilance -- Regulatory aspects of pharmacovigilance -- International collaboration -- Clinical aspects of adverse drug reactions -- Ethical and societal considerations -- Future directions -- Learning more about pharmacovigilance.
526			_aPharmaceutical Science
590			_aSumaiya Kainat Bintey Kohinoor
650	1	2	_aPharmacovigilance
650	2	2	_aDrug Monitoring _xmethods
650	2	2	_aDrug-Related Side Effects and Adverse Reactions
650	2	2	_aPharmaceutical Preparations _xstandards
700	1		_aHarrison-Woolrych, Mira, _eauthor.
942			_2lcc _cBK
999			_c30417 _d30417